JPRN-UMIN000001010已完成3 期
ong Term Follow-up Phase III Clinical Trial of TAP-144-SR (3M) in Patients with Spinal and Bulbar Muscular Atrophy (SBMA) - Long Term Follow-up Phase III Clinical Trial of Leuprorelin acetate in Patients with SBMA (JASMITT)
Department of Neurology, Nagoya University School of Medicine0 个研究点目标入组 152 人开始时间: 2008年2月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 152
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30years-old 至 71years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1) Patients who have met the termination criteria for the double-blind placebo-controlled phase III clinical trial. 2) Patients who have taken LH-RH agonists, testosterone drugs, 5-alpha-reductase inhibitors, anti-androgen drugs estrogen drugs or unapproved drugs after the recruitment of the double-blind placebo-controlled phase III clinical trial 3) Patients who have undergone operations (eg. orchiectomy), which reduce serum testosterone levels. 4) Patients who are unable to undergo videofluorography. 5) Patients who are diagnosed being depressed by M.I.N.I. Japanese version 5.0.0 major depression episode. 6) Patients who have severe complications. 7) Patients with past medical history of allergy to trial drugs in double-blind placebo-controlled phase III clinical trial. 8) Patients who are not appropriate to participate to the trial.
研究者
相似试验
进行中（未招募）
不适用
A phase 3, open-label 96-week extension study of the safety of apricitabine in treatment-experienced HIV-1 infected patients who have completed protocol AVX-301 or AVX-302 or who have met the criteria for open-label access to ATC because ofvirologic failure/lack of response. - AVX-303HIV-1MedDRA version: 9.1Level: LLTClassification code 10064446Term: HIV infection WHO clinical stage IEUCTR2008-001486-28-FRAvexa Limited1,866
进行中（未招募）
不适用
A phase 3, open-label 96-week extension study of the safety of apricitabine in treatment-experienced HIV-1 infected patients who have completed protocol AVX-301 or AVX-302 or who have met the criteria for open-label access to ATC because ofvirologic failure/lack of response. - 303HIV-1MedDRA version: 9.1Level: LLTClassification code 10064446Term: HIV infection WHO clinical stage IEUCTR2008-001486-28-BEAvexa Limited1,866
进行中（未招募）
不适用
A phase 3, open-label 96-week extension study of the safety of apricitabine in treatment-experienced HIV-1 infected patients who have completed protocol AVX-301 or AVX-302 or who have met the criteria for open-label access to ATC because ofvirologic failure/lack of response. - 303HIV-1MedDRA version: 9.1Level: LLTClassification code 10064446Term: HIV infection WHO clinical stage IEUCTR2008-001486-28-DEAvexa Limited1,866
进行中（未招募）
不适用
A phase 3, open-label 96-week extension study of the safety of apricitabine in treatment-experienced HIV-1 infected patients who have completed protocol AVX-301 or AVX-302 or who have met the criteria for open-label access to ATC because ofvirologic failure/lack of response. - 303HIV-1MedDRA version: 9.1Level: LLTClassification code 10064446Term: HIV infection WHO clinical stage IEUCTR2008-001486-28-GBAvexa Limited1,866
进行中（未招募）
3 期
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone LymphomaFollicular Lymphoma, Marginal Zone LymphomaJPRN-jRCT2021210065Eiji Ueda618